Cardinal Health lifts EPS outlook to $13 as specialty drug profits surge 17%

Cardinal Health, Inc. (NYSE: CAH) reported first-quarter fiscal 2027 revenue of $67.5 billion, an increase of 5% year on year, as stronger demand for branded and specialty medicines lifted profitability across its pharmaceutical distribution operations. The American healthcare services and products company increased its annual non-GAAP diluted earnings forecast to between $12.80 and $13 per share, following 28% growth in quarterly adjusted earnings per share. Shares closed 2.25% higher at $267.83 on November 5, 2026, reflecting a positive response to the company’s operating momentum and improved guidance.

The results nevertheless reveal uneven performance across Cardinal Health’s businesses. Pharmaceutical and Specialty Solutions segment profit increased 17% to $783 million, while profit in Global Medical Products and Distribution declined 28% to $33 million. The divergence illustrates the increasing importance of specialty pharmaceutical distribution and related services to the company’s earnings profile.

Cardinal Health also completed a $500 million accelerated share-repurchase programme during the quarter and reported stronger operating cash flow. These developments support the earnings outlook, but they require careful interpretation because lower share count and a reduced effective tax rate contributed to earnings-per-share growth. Investors must distinguish genuine operating improvements from financial factors that increase reported per-share earnings without proportionate growth in the underlying business.

Why did Cardinal Health’s profit grow faster than its $67.5bn revenue?

Cardinal Health reported revenue of $67.513 billion for the quarter ended September 30, 2026, compared with $64.009 billion a year earlier. GAAP operating earnings increased 13% to $753 million, while non-GAAP operating earnings advanced 17% to approximately $1 billion. The faster increase in profit relative to sales suggests that the company is improving its ability to generate earnings from its high-volume distribution network.

Gross profit increased from approximately $2.319 billion to $2.596 billion, representing growth of almost 12%. This outpaced the 5% increase in revenue, indicating a more favourable relationship between distribution revenue and the cost of products sold. The improvement can be commercially important for healthcare distributors, where enormous sales volumes typically generate comparatively narrow operating margins.

Cardinal Health’s quarterly GAAP net income attributable to shareholders increased 23% to $554 million, while diluted earnings per share rose 27% to $2.38. On an adjusted basis, attributable net income increased 24% to $759 million, and diluted earnings per share rose 28% to $3.26. The differences demonstrate that profit growth is reaching shareholders, although share repurchases contributed to the higher per-share increase.

The company’s effective tax rate also declined to 19.2% from 24.1% a year earlier. On a non-GAAP basis, the rate fell to 18.5% from 21.9%. This reduction supported after-tax earnings and should be considered when assessing the sustainability of the reported growth rate.

Cardinal Health’s operating performance is clearly improving, but the quality of that improvement depends on the balance between higher distribution margins, cost management, favourable tax effects and share-count reduction. The company’s guidance suggests confidence in continuing progress, although the composition of future earnings will remain important.

How are specialty medicines changing Cardinal Health’s pharmaceutical distribution business?

The Pharmaceutical and Specialty Solutions segment generated approximately $62.6 billion in quarterly revenue, compared with $59.2 billion a year earlier. The 6% increase was driven by higher sales of branded and specialty medicines to existing customers. Segment profit increased 17% to $783 million, substantially outpacing revenue growth.

Specialty pharmaceuticals often involve complex distribution requirements, including temperature-sensitive products, specialised handling and services tailored to healthcare providers. These requirements can create opportunities for distributors to differentiate themselves beyond basic product transportation. Strong demand can also increase the importance of reliable logistics, inventory availability and customer relationships.

Cardinal Health’s results demonstrate how specialty medicines can influence the financial performance of a large healthcare distributor. Higher revenue in these categories may improve the earnings mix, particularly when accompanied by effective purchasing and distribution arrangements. However, the relationship between product pricing and distributor profitability is complex, and higher drug spending does not automatically translate into proportionately higher margins.

The company attributed the segment’s profit improvement partly to branded and specialty products and positive performance in its generics programme. This combination suggests that earnings growth is being supported by several components of pharmaceutical distribution rather than a single product category.

Management increased its full-year Pharmaceutical and Specialty Solutions segment profit-growth forecast to 10% to 12%, compared with its previous expectation of 8% to 11%. The upgrade reinforces the significance of this business to Cardinal Health’s financial outlook. Investors will be watching whether strong specialty demand and favourable generics economics can continue supporting profitability.

Why is Cardinal Health’s medical products business struggling despite stable sales?

Global Medical Products and Distribution generated approximately $3.2 billion in quarterly revenue, broadly unchanged from the prior year. However, segment profit declined from $46 million to $33 million, representing a 28% decrease. The weaker result contrasts sharply with the improvement in pharmaceutical distribution.

Cardinal Health attributed the decline partly to unfavourable distribution and foreign-exchange effects, partially offset by growth in Cardinal Health-branded products. The results indicate that flat sales did not translate into stable profitability because the costs and composition of revenue changed. This is particularly relevant for businesses with distribution infrastructure and other operating expenses that cannot be reduced immediately.

Medical products and distribution can face different competitive pressures from pharmaceutical wholesale operations. Healthcare customers are highly sensitive to costs, while logistics, sourcing and inventory requirements influence margins. A deterioration in product mix or distribution economics can consequently reduce profit even when revenue remains broadly unchanged.

The weakness also demonstrates why diversified healthcare companies require segment-level analysis. Consolidated operating profit increased during the quarter, but that improvement does not establish that every part of the business is strengthening. The medical-products division remains an area where management must demonstrate greater operating consistency.

For investors, the question is whether the decline represents temporary pressure or a more persistent challenge. Improvements in branded product sales, distribution efficiency and foreign-exchange conditions could help profitability recover. However, the latest results do not provide sufficient evidence to assume that a recovery is already underway.

Can Cardinal Health’s other healthcare services become a larger source of profit?

Cardinal Health’s other businesses generated approximately $1.8 billion in quarterly revenue, an increase of 7%, while segment profit rose 16% to $193 million. The portfolio includes Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics. These activities provide exposure to specialised healthcare services beyond conventional pharmaceutical distribution.

The company’s nuclear pharmacy and precision-health operations support the distribution and handling of products used in diagnostic and treatment applications. Its at-home business serves healthcare needs outside traditional hospital settings, while OptiFreight Logistics provides shipping and logistics-related services to healthcare customers. Each business has different commercial drivers and operating requirements.

The performance is significant because the smaller businesses contribute a meaningful amount of profit relative to their reported revenue. Cardinal Health’s other activities generated $193 million in segment profit on approximately $1.8 billion of sales, compared with $783 million on $62.6 billion in the Pharmaceutical and Specialty Solutions segment. Although segment definitions and costs differ, the comparison illustrates how smaller service-oriented activities can provide a different earnings profile.

Management raised its annual profit-growth forecast for these businesses to 17% to 20%, compared with the previous range of 15% to 18%. It also increased expected revenue growth to 12% to 14%. These upgrades suggest that specialised services are becoming an increasingly important part of the company’s broader earnings strategy.

Cardinal Health has also entered into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health. This represents an important step towards maintaining a major customer relationship, but it should not be described as a fully completed definitive renewal. The eventual contractual arrangements and their financial terms will determine the longer-term contribution.

How will acquisitions and share repurchases influence Cardinal Health’s earnings?

Cardinal Health expects to complete its acquisition of AdaptHealth’s Diabetes Health business during the third quarter of fiscal 2027. The proposed transaction would expand its activities in home healthcare and diabetes-related products, supporting the company’s efforts to broaden its service portfolio. Completion remains prospective, and the expected commercial contribution should not be treated as revenue already earned.

The company also completed a $500 million accelerated share-repurchase programme during the first quarter. Management reduced its full-year diluted weighted-average share-count assumption to between 231 million and 232 million, compared with its earlier expectation of approximately 233 million. A lower share count can increase earnings per share even when total company profit remains unchanged.

Cardinal Health generated approximately $1.398 billion in cash from operating activities during the quarter, compared with $973 million a year earlier. The increase provides additional financial support for investment, acquisitions and shareholder returns. However, cash generation must be evaluated alongside working-capital movements and the company’s capital requirements.

The group’s non-GAAP adjusted free cash flow reached approximately $1.583 billion. This measure includes company-defined adjustments and should not be confused with unadjusted cash flow after capital expenditure. The difference matters because investors assessing the company’s capacity for sustainable distributions need to understand the adjustments included in management’s preferred measure.

The combination of stronger operating cash generation, improved earnings and a completed share repurchase supports Cardinal Health’s financial flexibility. Nevertheless, maintaining a balance between acquisitions, investment and capital returns requires careful allocation of cash. The ultimate value of this strategy depends on whether additional businesses generate attractive returns and whether buybacks are completed at economically sensible prices.

What does Cardinal Health’s upgraded $13 earnings outlook mean for investors?

Cardinal Health increased its fiscal 2027 non-GAAP earnings guidance to $12.80 to $13 per diluted share, compared with its previous forecast of $12.40 to $12.60. The new range represents expected growth of approximately 14% to 15% from reported fiscal 2026 results, or 17% to 19% against a prior-year baseline adjusted to exclude tariff refunds. The two comparisons use different baselines and should not be presented interchangeably.

The company also lowered its expected annual non-GAAP effective tax-rate range to 18.5% to 19.5%, from 19% to 20%. Together with the smaller expected share count, this contributes to the upgraded per-share forecast. Investors should therefore evaluate whether underlying operating profit growth continues to support the earnings trajectory independently of these financial effects.

Shares closed at $267.83 on November 5, an increase of approximately 2.25% for the session. The stock had traded as high as $286.29 during the day, demonstrating considerable intraday volatility despite the positive closing performance. The market reaction suggests that stronger results were welcomed, although valuation expectations and profit-taking also influenced trading.

Cardinal Health’s competitive position depends on maintaining customer relationships, strengthening specialty capabilities and managing the economics of its distribution infrastructure. The proposed renewal with CVS Health, pending acquisition activity and growth in higher-value services offer potential support. However, medical-products profitability and the effects of tax and share-count changes remain important qualifications to the headline earnings improvement.

The latest results reveal a company producing stronger profit from a massive distribution base while gradually diversifying towards specialised healthcare services. Its improved guidance provides evidence of management confidence, but the most durable investment case will require continued operating profit growth and resilient cash generation. Investors should monitor the profitability of individual businesses rather than relying solely on the rising earnings-per-share forecast.